
Krsnaa Diagnostics Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
No
Order
Yes
Capex
Yes
2 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 2- Krsnaa Diagnostics expects a revenue growth CAGR of around 30% for FY '25, continuing the current growth trajectory.
- Expansion into more states and large projects such as Assam, Odisha, Rajasthan, and Maharashtra underpin this growth.
- New projects and tenders will add to gross block and incremental revenues as centers get implemented and mature.
- The company is becoming selective in tender participation, focusing on those aligned with financial metrics.
- B2C vertical is in early stages but expected to grow as brand acceptance and package sales increase.
- Rajasthan tender's revenue meaningful contribution expected in the second half or Q4 of FY '25 after court decision and lab installations.
- Increasing volume is a key growth driver, particularly given the PPP model which offers significant patient volumes.
- The test mix is expected to remain around 60-65% radiology and 35-40% pathology, with a target to approach a 50-50 mix.
See what Krsnaa Diagnostics management said on margin guidance — free account, 30 seconds.
Fundraise plans
No- Krsnaa Diagnostics aims to remain largely debt-free, relying primarily on internal accruals and vendor credit for funding.
- Debt may be considered if it proves to be a more efficient financing option for specific projects.
- Discussions are underway to adopt an asset-light pay-per-use model for equipment, reducing upfront capex needs.
- For upcoming capex, including potential Rajasthan tender-related investments, a combination of internal funds, vendor credit, and possible debt will be utilized.
- No explicit mention of raising funds through equity is noted in the provided transcript.
- The company emphasizes minimizing debt and maintaining a strong balance sheet while pursuing growth opportunities.
See what Krsnaa Diagnostics management said on order book — free account, 30 seconds.
Capex plans
Yes- Planned capex for FY '25 (2024-25) is INR150-200 crores, excluding Rajasthan tender.
- Rajasthan tender capex, if won, is an additional INR200-250 crores, potentially raising total capex to INR450-500 crores over approximately one year.
- Capex mainly towards installing large, capex-heavy equipment such as analyzers and immunoassay machines.
- Exploring asset-light strategies including pay-per-use or lease models for equipment to reduce outright purchases.
- Capex funding through a mix of internal accruals, vendor financing, and possible debt if efficient, though company aims to remain largely debt-free.
- New projects like Maharashtra MRI/CT and other state tenders will require incremental capex within the stated range.
- Focus remains on selective tender participation aligned with financial metrics to optimize return on capital employed (ROCE).
Track Krsnaa Diagnostics — get its next earnings analysis in your feed
How does Krsnaa Diagnostics rank vs peers in Healthcare Services?
Pro featureHow does Krsnaa Diagnostics rank in Healthcare Services?
Compare Krsnaa Diagnostics against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Krsnaa Diagnostics's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.